The medical management of menopause: To treat or not to treat?

Annals of the New York Academy of Sciences

Volumn 1127, Issue , 2008, Pages 134-139

  Barlow, David H ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Breast cancer; Cardiovascular disease; Coronary heart disease; Estrogen; Fracture; Hormone therapy; Hysterectomy; Menopause; Osteoporosis; Postmenopause; Progestin; Progestogen; Randomized controlled trial; Stroke; Vasomotor symptoms

Indexed keywords

ESTROGEN; PROGESTERONE;

BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COLON CANCER; CONFERENCE PAPER; DISEASE MANAGEMENT; FRACTURE; HORMONAL THERAPY; HUMAN; MENOPAUSAL SYNDROME; MENOPAUSE; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; STROKE;

EID: 42449157169     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1434.002     Document Type: Conference Paper

References (24)

1. Rossouw, J.E., G.L. Anderson, R.L. Prentice & Writing Group for the Women's Health Initiative Investigators. 2002. Risks and benefits of estrogen plus progestin in health postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 : 321 333.
2. Anderson, G.L., M. Limacher, A.R. Assaf & Women's The Women's Health Initiative Steering Committee. 2004. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 291 : 1701 1712.
3. Kaplan, B., Y. Yogev, R. Orvieto, et al. 2004. Effect of the WHI study on the attitude of Israeli gynaecologists to hormonal therapy during menopause. Clin. Exp. Obstet. Gynecol. 31 : 267 268.
4. Blümel, J.E., C. Castelo-Branco, P.A. Chedraui, et al. 2004. Patients' and clinicians' attitudes after the Women's Health Initiative study. Menopause 11 : 57 61.
5. Oldenhave, A., L.J. Kaszmann & A.A. Haspels. 1993. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am. J. Obstet. Gynecol. 168 : 772 780.
6. Cauley, J.A., J. Robbins, Z. Chen, et al. & Women's Health Initiative Investigators. 2003. Effects of estrogen plus progestin on risk of fracture and bone mineral density the Women's Health Initiative randomized trial. JAMA 290 : 1729 1738.
7. Manson, J.E., J. Hsia, K.C. Johnson, et al. & For the Women's Health Initiative Investigators. 2003. Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med. 349 : 523 534.
8. Wassertheil-Smoller, S., S.L. Hendrix, M. Limacher, et al. & Women's Health Initiative Investigators. 2003. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 289 : 2673 2684.
9. Chlebowski, R.T., S.L. Hendrix, R.D. Langer, et al. & For the WHI Investigators. 2003. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 289 : 3243 3253.
10. Hulley, S., D. Grady, T. Bush, et al. 1998. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 : 606 613.
11. Pannay, N., O. Ylikorkala, D.F. Archer, et al. 2007. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric 10 : 120 131.
12. Utian, W.H., D. Shoupe, G. Bachmann, et al. 2001. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil. Steril. 75 : 1065 1079.
13. Archer, D.F., M. Dorin, V. Lewis, et al. 2001. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil. Steril. 75 : 1080 1087.
14. Shumaker, S.A., C. Legault, S.R. Rapp, et al. 2003. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289 : 2651 2662.
15. Grodstein, F., J.E. Manson & M.J. Stampfer. 2006. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J. Women's Health 15 : 35 44.
16. Rossouw, J.E., R.L. Prentice, J.E. Manson, et al. 2007. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297 : 1465 1477.
17. Manson, J.E., M.A. Allison, J.E. Rossouw, et al. 2007. Estrogen therapy and coronary-artery calcification. N. Engl. J. Med. 356 : 2639 2641.
18. Mikkola, T.S. & T.B. Clarkson. 2002. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc. Res. 53 : 605 619.
19. Collins, P., G. Rosanp, C. Casey, et al. 2007. Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. Eur. Heart J. doi :.
20. Zandi, P.D., M.C. Carlson, B.L. Plassman, et al. 2002. Hormone replacement therapy and incidence of Alzheimer's disease in older women. The Cache County Study. JAMA 288 : 2123 2139.
21. Henderson, V.W. 1997. The epidemiology of estrogen replacement therapy and Alzheimer's disease. Neurology 48 : S27 S35.
22. Bagger, Y.Z., L.B. Tankó, P. Alexandersen, et al. 2004. Two to three years of HRT in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: PERF study. Bone 34 : 728 735.
23. Alexandersen, P., L.B. Tankó, Y.Z. Bagger, et al. 2006. Long term impact of two to three years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. Climacteric 9 : 108 118.
24. Bagger, Y.Z., C. Christiansen, P. Alexandersen, et al. 2005. Early postmenopausal hormone therapy may prevent cognitive impairment later in life. Menopause 12 : 12 17.